Meeting
2018 ASCO Annual Meeting
First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.
Authors
Gabriel N. Hortobagyi
The University of Texas MD Anderson Cancer Center, Houston, TX
Gabriel N. Hortobagyi , Shani Paluch-Shimon , Katarina Petrakova , Cristian Villanueva , Arlene Chan , Arnd Nusch , Yoon Sim Yap , Lowell Hart , Anne Favret , Norbert Marschner , Gabe S. Sonke , Hege Oma Ohnstad , Carlos Arteaga , Fei Su , Wei He , Michelle Kristine Miller , Salomon M. Stemmer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT01958021
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1022)
DOI
10.1200/JCO.2018.36.15_suppl.1022
Abstract #
1022
Poster Bd #
103
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
First Author: Kelvin K H Bao
Poster
2019 ASCO Annual Meeting
First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.
First Author: Joyce O'Shaughnessy
Poster
2019 ASCO Annual Meeting
In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.
First Author: Yen-Shen Lu
Poster
2018 ASCO Annual Meeting
Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.
First Author: Michelino DeLaurentiis